Se connecter Inscription gratuite

Panbela Therapeutics Quick ratio

Quel est le Quick ratio de Panbela Therapeutics?

Le Quick ratio de Panbela Therapeutics Inc. est 0.21

Quelle est la définition de Quick ratio?



«Quick ratio» est le ratio de liquidité qui mesure la capacité d'une entreprise à utiliser ses actifs rapides pour faire face à ses obligations à court terme immédiatement.

The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.

Quick ratio des entreprises dans Health Care secteur sur NASDAQ par rapport à Panbela Therapeutics

Que fait Panbela Therapeutics?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Entreprises avec quick ratio similaire à Panbela Therapeutics